Venetoclax combination approved for elderly AML

(Dana-Farber Cancer Institute) Older patients with acute myeloid leukemia (AML) often aren't healthy enough to receive intensive chemotherapy, and gentler treatments aren't very effective in treating this aggressive blood cancer.But a new option -- a combination of a standard drug and the novel agent venetoclax -- has been granted accelerated approval by the Food and Drug Administration for such patients after a large, multicenter phase 1 clinical trial showed the combination had 'promising efficacy' and was well tolerated in older AML patients.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news